
Guido Antonelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3608699/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comparative evaluation of molecular methods for the quantitative measure of torquetenovirus viremia, the new surrogate marker of immune competence. Journal of Medical Virology, 2022, 94, 491-498.	5.0	17
2	Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732110657.	1.0	4
3	Distribution of Interferon Lambda 4 Single Nucleotide Polymorphism rs11322783 Genotypes in Patients with COVID-19. Microorganisms, 2022, 10, 363.	3.6	4
4	HPV Vaccination after Primary Treatment of HPV-Related Disease across Different Organ Sites: A Multidisciplinary Comprehensive Review and Meta-Analysis. Vaccines, 2022, 10, 239.	4.4	24
5	Analysis of serum microRNAs and rs2910164 GC single-nucleotide polymorphism of miRNA-146a in COVID-19 patients. Journal of Immunoassay and Immunochemistry, 2022, 43, 347-364.	1.1	7
6	Reflections after 2Âyears of COVIDâ€19 pandemic. Reviews in Medical Virology, 2022, 32, e2351.	8.3	1
7	Phylogeography and genomic epidemiology of SARS-CoV-2 in Italy and Europe with newly characterized Italian genomes between February-June 2020. Scientific Reports, 2022, 12, 5736.	3.3	6
8	Pfizer-BioNTech COVID-19 Vaccine in Gynecologic Oncology Patients: A Prospective Cohort Study. Vaccines, 2022, 10, 12.	4.4	4
9	Safety of Multiple Vaccinations and Durability of Vaccine-Induced Antibodies in an Italian Military Cohort 5 Years after Immunization. Biomedicines, 2022, 10, 6.	3.2	6
10	Antiâ€IFNâ€Î±/â€Ï‰ neutralizing antibodies from COVIDâ€19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity. European Journal of Immunology, 2022, 52, 1120-1128.	2.9	29
11	Convalescent plasma for haematological patients with SARS-CoV-2 pneumonia and severe depletion of B-cell lymphocytes following anti-CD20 therapy: a single-centre experience and review of the literature New Microbiologica, 2022, 45, 62-72.	0.1	3
12	High prevalence of Merkel cell polyomavirus is associated with dysregulation in transcript levels of TLR9 and type I IFNs in a large cohort of CF patients from the Italian (Lazio) reference center for cystic fibrosis. Microbial Pathogenesis, 2022, 169, 105644.	2.9	1
13	High frequency of neutralizing antibodies to type I Interferon in HIV-1 patients hospitalized for COVID-19. Clinical Immunology, 2022, 241, 109068.	3.2	5
14	SARS oVâ€⊋ presence in seminal fluid: Myth or reality. Andrology, 2021, 9, 23-26.	3.5	54
15	SARSâ€CoVâ€2 diagnostics in the virology laboratory of a University Hospital in Rome during the lockdown period. Journal of Medical Virology, 2021, 93, 886-891.	5.0	12
16	What is the optimal usage of coronavirus disease 2019 convalescent plasma donations?. Clinical Microbiology and Infection, 2021, 27, 163-165.	6.0	11
17	Klebsiella pneumoniae infections in COVID-19 patients: a 2-month retrospective analysis in an Italian hospital. International Journal of Antimicrobial Agents, 2021, 57, 106245.	2.5	42
18	SARS-CoV-2 diagnostics: Some reflections on current assays. Diagnostic Microbiology and Infectious Disease, 2021, 99, 115237.	1.8	8

#	Article	IF	CITATIONS
19	Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro. Pharmacological Research, 2021, 163, 105255.	7.1	88
20	Susceptibility Testing of Colistin for Acinetobacter baumannii: How Far Are We from the Truth?. Antibiotics, 2021, 10, 48.	3.7	6
21	Diagnosis; Future Prospects on Direct Diagnosis. , 2021, , 112-117.		Ο
22	SARS-CoV-2 Entry Genes Expression in Relation with Interferon Response in Cystic Fibrosis Patients. Microorganisms, 2021, 9, 93.	3.6	4
23	Molecular diagnosis of SARS-CoV-2 in seminal fluid. Journal of Endocrinological Investigation, 2021, 44, 2675-2684.	3.3	23
24	Differential induction of type I and III interferon genes in the upper respiratory tract of patients with coronavirus disease 2019 (COVID-19). Virus Research, 2021, 295, 198283.	2.2	26
25	ACE2 expression is related to the interferon response in airway epithelial cells but is that functional for SARS-CoV-2 entry?. Cytokine, 2021, 140, 155430.	3.2	13
26	Asymptomatic individuals positive for anti-SARS-CoV-2 antibodies negative on molecular swab. Lancet Microbe, The, 2021, 2, e178.	7.3	2
27	Alteration of type I interferon response is associated with subclinical atherosclerosis in virologically suppressed HIVâ€1â€infected male patients. Journal of Medical Virology, 2021, 93, 4930-4938.	5.0	5
28	Dolutegravir-Based Regimen for Maintenance of Viral Suppression in People Living with HIV: 48-Week Results in Real-Life Setting. AIDS Research and Human Retroviruses, 2021, 37, 478-485.	1.1	5
29	KI and WU Polyomavirus in Respiratory Samples of SARS-CoV-2 Infected Patients. Microorganisms, 2021, 9, 1259.	3.6	3
30	COVID-19 infodemics: the role of mainstream and social media. Clinical Microbiology and Infection, 2021, 27, 1568-1569.	6.0	9
31	Molecular epidemiology of NDM-5-producing Escherichia coli high-risk clones identified in two Italian hospitals in 2017-2019. Diagnostic Microbiology and Infectious Disease, 2021, 100, 115399.	1.8	12
32	CRISPR/Cas9 Ablation of Integrated HIV-1 Accumulates Proviral DNA Circles with Reformed Long Terminal Repeats. Journal of Virology, 2021, 95, e0135821.	3.4	13
33	The Synergistic Effect of Time of Exposure, Distance and No Use of Personal Protective Equipment in the Determination of SARS-CoV-2 Infection: Results of a Contact Tracing Follow-Up Study in Healthcare Workers. International Journal of Environmental Research and Public Health, 2021, 18, 9456.	2.6	3
34	Evolutionary Trajectories toward Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2021, 65, e0057421.	3.2	41
35	Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?. Journal of Thrombosis and Thrombolysis, 2021, 52, 105-110.	2.1	18
36	Potential IFNÎ ³ Modulation of Inflammasome Pathway in Chlamydia trachomatis Infected Synovial Cells. Life, 2021, 11, 1359.	2.4	4

#	Article	IF	CITATIONS
37	Chest computed tomography score, cycle threshold values and secondary infection in predicting COVID-19 mortality. New Microbiologica, 2021, 44, 145-154.	0.1	2
38	Transmitted drug resistance mutations and trends of HIV-1 subtypes in treatment-naÃ⁻ve patients: A single-centre experience. Journal of Global Antimicrobial Resistance, 2020, 20, 298-303.	2.2	13
39	Lack of Marseillevirus DNA in immunocompetent and immunocompromised Italian patients. Journal of Medical Virology, 2020, 92, 187-190.	5.0	4
40	Detection of SARS-COV N2 Gene: Very low amounts of viral RNA or false positive?. Journal of Clinical Virology, 2020, 133, 104660.	3.1	27
41	High abundance of genus Prevotella is associated with dysregulation of IFN-I and T cell response in HIV-1-infected patients. Aids, 2020, 34, 1467-1473.	2.2	14
42	Modulation of Phenylalanine and Tyrosine Metabolism in HIV-1 Infected Patients with Neurocognitive Impairment: Results from a Clinical Trial. Metabolites, 2020, 10, 274.	2.9	7
43	Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19. Frontiers in Medicine, 2020, 7, 389.	2.6	152
44	Differential toll like receptor expression in cystic fibrosis patients' airways during rhinovirus infection. Journal of Infection, 2020, 81, 726-735.	3.3	4
45	COVID-19 in Patients with Hematologic Disorders Undergoing Therapy: Perspective of a Large Referral Hematology Center in Rome. Acta Haematologica, 2020, 143, 574-582.	1.4	14
46	SARS-CoV-2 infection: diagnostic testing results occasionally require special attention. Emerging Microbes and Infections, 2020, 9, 1955-1957.	6.5	2
47	Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection. Medicine (United States), 2020, 99, e21803.	1.0	18
48	Anosmia and Ageusia as Predictive Signs of COVID-19 in Healthcare Workers in Italy: A Prospective Case-Control Study. Journal of Clinical Medicine, 2020, 9, 2870.	2.4	27
49	Usefulness of bronchoalveolar lavage in suspect COVID-19 repeatedly negative swab test and interstitial lung disease. Journal of Global Antimicrobial Resistance, 2020, 23, 67-69.	2.2	9
50	Redondovirus DNA in human respiratory samples. Journal of Clinical Virology, 2020, 131, 104586.	3.1	19
51	A Multispecies Cluster of VIM-1 Carbapenemase-Producing <i>Enterobacterales</i> Linked by a Novel, Highly Conjugative, and Broad-Host-Range IncA Plasmid Forebodes the Reemergence of VIM-1. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	18
52	Novel Insights and Features of the NDM-5-Producing Escherichia coli Sequence Type 167 High-Risk Clone. MSphere, 2020, 5, .	2.9	39
53	Antibiotic Resistance and Therapy for H. pylori Infection in Immigrant Patients Treated in Italy. Journal of Clinical Medicine, 2020, 9, 1299.	2.4	8
54	Type I interferons can be detected in respiratory swabs from SARS-Cov-2 infected patients. Journal of Clinical Virology, 2020, 128, 104450.	3.1	10

#	Article	IF	CITATIONS
55	Seroprevalence of group B Coxsackieviruses: Retrospective study in an Italian population. Journal of Medical Virology, 2020, 92, 3138-3143.	5.0	9
56	Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome–Coronavirus 2 In Vitro When Administered After Virus Infection. Journal of Infectious Diseases, 2020, 222, 722-725.	4.0	61
57	Effect of low or high doses of lowâ€molecularâ€weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVIDâ€19. British Journal of Haematology, 2020, 190, e214-e218.	2.5	25
58	Rifabutin-Based Triple Therapy Or Bismuth-Based Quadruple Regimen As Rescue Therapies For Helicobacter pylori Infection. European Journal of Internal Medicine, 2020, 81, 50-53.	2.2	17
59	No detection of SARS-CoV-2 in cystic fibrosis patients at the Regional (Lazio) Reference Center for CF in Italy. Journal of Cystic Fibrosis, 2020, 19, 837-838.	0.7	8
60	Novel Variants of Respiratory Syncytial Virus A ON1 Associated With Increased Clinical Severity of Bronchiolitis. Journal of Infectious Diseases, 2020, 222, 102-110.	4.0	21
61	Interferon-Î ³ Possesses Anti-Microbial and Immunomodulatory Activity on a Chlamydia trachomatis Infection Model of Primary Human Synovial Fibroblasts. Microorganisms, 2020, 8, 235.	3.6	6
62	The SARS-CoV-2 epidemic: how the Italian public is being informed. Clinical Microbiology and Infection, 2020, 26, 791-792.	6.0	5
63	Study of SARS-CoV-2 in semen and urine samples of a volunteer with positive naso-pharyngeal swab. Journal of Endocrinological Investigation, 2020, 43, 1819-1822.	3.3	207
64	Insights into the Role of Innate Immunity in Cervicovaginal Papillomavirus Infection from Studies Using Gene-Deficient Mice. Journal of Virology, 2020, 94, .	3.4	13
65	Rescue Therapies for Helicobacter pylori Infection in Foreign Patients Treated in Italy. Journal of Clinical Gastroenterology, 2020, Publish Ahead of Print, 865-868.	2.2	2
66	Decreased Type I Interferon Production by Plasmacytoid Dendritic Cells Contributes to Severe Dengue. Frontiers in Immunology, 2020, 11, 605087.	4.8	11
67	Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators. Journal of Virology, 2019, 93, .	3.4	16
68	Merkel Cell Polyomavirus DNA Detection in Respiratory Samples: Study of a Cohort of Patients Affected by Cystic Fibrosis. Viruses, 2019, 11, 571.	3.3	6
69	Candida blood stream infections observed between 2011 and 2016 in a large Italian University Hospital: A time-based retrospective analysis on epidemiology, biofilm production, antifungal agents consumption and drug-susceptibility. PLoS ONE, 2019, 14, e0224678.	2.5	16
70	Collaborative national multicenter for the identification of conversion factors from copies/mL to international units/mL for the normalization of HCMV DNA load. Diagnostic Microbiology and Infectious Disease, 2019, 95, 152-158.	1.8	11
71	Increased expression of IL-32 correlates with IFN-γ, Th1 and Tc1 in virologically suppressed HIV-1-infected patients. Cytokine, 2019, 120, 273-281.	3.2	12
72	HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review. Viruses, 2019, 11, 1049.	3.3	18

#	Article	IF	CITATIONS
73	Copy-Years Viremia and Risk of Virological Failure in Long-Term–Treated HIV Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 423-428.	2.1	3
74	Increased IL-17 and/or IFN-γ producing T-cell subsets in gut mucosa of long-term-treated HIV-1-infected women. Aids, 2019, 33, 627-636.	2.2	7
75	How Respiratory Syncytial Virus Genotypes Influence the Clinical Course in Infants Hospitalized for Bronchiolitis. Journal of Infectious Diseases, 2019, 219, 526-534.	4.0	54
76	Virology: a scientific discipline facing new challenges. Clinical Microbiology and Infection, 2019, 25, 133-135.	6.0	4
77	Increased SAMHD1 transcript expression correlates with interferon-related genes in HIV-1-infected patients. Medical Microbiology and Immunology, 2019, 208, 679-691.	4.8	7
78	Future management of viral diseases: role of new technologies and new approaches in microbial interactions. Clinical Microbiology and Infection, 2019, 25, 136-141.	6.0	11
79	Low prevalence of Gemycircularvirus DNA in immunocompetent and immunocompromised subjects. New Microbiologica, 2019, 42, 118-120.	0.1	3
80	Interferon lambda4 polymorphism is not associated with human papillomavirus infection outcome. Virus Genes, 2018, 54, 319-322.	1.6	2
81	Interferon lambda receptor 1 (IFNL1R) transcript is highly expressed in rhinovirus bronchiolitis and correlates with disease severity. Journal of Clinical Virology, 2018, 102, 101-109.	3.1	21
82	Type I interferon and HIV: Subtle balance between antiviral activity, immunopathogenesis and the microbiome. Cytokine and Growth Factor Reviews, 2018, 40, 19-31.	7.2	28
83	Acute bronchiolitis: Influence of viral coâ€infection in infants hospitalized over 12 consecutive epidemic seasons. Journal of Medical Virology, 2018, 90, 631-638.	5.0	45
84	Early Post-Transplant Torquetenovirus Viremia Predicts Cytomegalovirus Reactivations In Solid Organ Transplant Recipients. Scientific Reports, 2018, 8, 15490.	3.3	59
85	Type I/II Interferon in HIV-1-Infected Patients: Expression in Gut Mucosa and in Peripheral Blood Mononuclear Cells and Its Modification upon Probiotic Supplementation. Journal of Immunology Research, 2018, 2018, 1-7.	2.2	14
86	Yersinia enterocolitica in Italy: A Case of Septicemia and Abdominal Aortic Aneurysm Infection. Frontiers in Medicine, 2018, 5, 156.	2.6	6
87	Respiratory syncytial virus. Minerva Pediatrica, 2018, 70, 553-565.	2.7	21
88	John Cunningham virus: an overview on biology and disease of the etiological agent of the progressive multifocal leukoencephalopathy. New Microbiologica, 2018, 41, 179-186.	0.1	19
89	Antiviral activity of the combination of interferon and ribavirin against chikungunya virus: are the results conclusive?. Journal of Infectious Diseases, 2017, 215, jiw579.	4.0	5
90	Probiotic supplementation promotes a reduction in Tâ€cell activation, an increase in Th17 frequencies, and a recovery of intestinal epithelium integrity and mitochondrial morphology in ARTâ€treated HIVâ€1â€positive patients. Immunity, Inflammation and Disease, 2017, 5, 244-260.	2.7	84

#	Article	IF	CITATIONS
91	Rhinovirus species/genotypes and interferon-λ: subtypes, receptor and polymorphisms – missing pieces of the puzzle of childhood asthma?. European Respiratory Journal, 2017, 49, 1700060.	6.7	0
92	Consolidation of molecular testing in clinical virology. Expert Review of Anti-Infective Therapy, 2017, 15, 387-400.	4.4	12
93	A pilot study on the effects of probiotic supplementation on neuropsychological performance and micro <scp>RNA</scp> â€29aâ€c levels in antiretroviralâ€treated <scp>HIV</scp> â€lâ€infected patients. Brain an Behavior, 2017, 7, e00756.	ո֎.2	45
94	Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013–2016: Impact on susceptibility to first-line strategies including integrase strand-transfer inhibitors. Journal of Global Antimicrobial Resistance, 2017, 10, 106-112.	2.2	17
95	Respiratory syncytial virus bronchiolitis, weather conditions and air pollution in an Italian urban area: An observational study. Environmental Research, 2017, 158, 188-193.	7.5	85
96	Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns. BMC Infectious Diseases, 2017, 17, 581.	2.9	34
97	Role of Interferons in Chronic Hepatitis C Infection. Current Drug Targets, 2017, 18, 844-850.	2.1	13
98	Bronchiolitis: Analysis of 10 consecutive epidemic seasons. Pediatric Pulmonology, 2016, 51, 1330-1335.	2.0	49
99	Dominant enrichment of phenotypically activated CD38 ⁺ HLA-DR ⁺ CD8 ⁺ T cells, rather than CD38 ⁺ HLA-DR ⁺ CD4 ⁺ T cells, in HIV/HCV coinfected patients on antiretroviral therapy. Journal of Medical Virology. 2016. 88. 1347-1356.	5.0	5
100	Cyclovirus Vietnam DNA in immunodeficient patients. Journal of Clinical Virology, 2016, 81, 12-15.	3.1	6
101	IFN-stimulated gene expression is independent of the IFNL4 genotype in chronic HIV-1 infection. Archives of Virology, 2016, 161, 3263-3268.	2.1	3
102	Emerging issues on hepatitis C virus infection after the introduction of the Directly Acting Antivirals. Clinical Microbiology and Infection, 2016, 22, 824-825.	6.0	0
103	MALDI-TOF MS Versus VITEK®2: Comparison of Systems for the Identification of Microorganisms Responsible for Bacteremia. Current Microbiology, 2016, 73, 843-850.	2.2	19
104	Comparative Analysis of Real-Time Polymerase Chain Reaction Methods to Typing HLA-B*57:01 in HIV-1-Positive Patients. AIDS Research and Human Retroviruses, 2016, 32, 654-657.	1.1	7
105	Integration of the viral genome into the host cell genome: a double-edged sword. Clinical Microbiology and Infection, 2016, 22, 296-298.	6.0	9
106	Investigation on torquetenovirus (TTV) microRNA transcriptome in vivo. Virus Research, 2016, 217, 18-22.	2.2	18
107	ISG15 expression correlates with HIV-1 viral load and with factors regulating T cell response. Immunobiology, 2016, 221, 282-290.	1.9	32
108	Frequent detection of high human papillomavirus DNA loads in oral potentially malignant disorders. Clinical Microbiology and Infection, 2016, 22, 95.e9-95.e15.	6.0	11

#	Article	IF	CITATIONS
109	Ebolavirus and evidence-based speculations. New Microbiologica, 2016, 39, 71-2.	0.1	1
110	Evaluation of performances of VERSANT HCV RNA 1.0 assay (kPCR) and Roche COBAS AmpliPrep/COBAS TaqMan HCV test v2.0 at low level viremia. New Microbiologica, 2016, 39, 224-227.	0.1	5
111	Viral Load in Infants Hospitalized for Respiratory Syncytial Virus Bronchiolitis Correlates with Recurrent Wheezing at Thirty-Six-Month Follow-Up. Pediatric Infectious Disease Journal, 2015, 34, 1131-1132.	2.0	21
112	Interplay between β herpesviruses and fungal infections in transplant patients: from the bench to the bedside. Future Virology, 2015, 10, 399-414.	1.8	3
113	Lack of usutu virus RNA in cerebrospinal fluid of patients with encephalitis of unknown etiology, Tuscany, Italy. Journal of Medical Virology, 2015, 87, 913-916.	5.0	4
114	Analysis of Th17 and Tc17 Frequencies and Antiviral Defenses in Gut-Associated Lymphoid Tissue of Chronic HIV-1 Positive Patients. Mediators of Inflammation, 2015, 2015, 1-11.	3.0	15
115	Trends in drug resistance-associated mutations in a real-life cohort of Italian patients infected with HIV-1. Journal of Global Antimicrobial Resistance, 2015, 3, 267-272.	2.2	7
116	Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use. Cytokine and Growth Factor Reviews, 2015, 26, 121-131.	7.2	43
117	MicroRNA-29 family expression and its relation to antiviral immune response and viro-immunological markers in HIV-1-infected patients. BMC Infectious Diseases, 2015, 15, 51.	2.9	26
118	Why do infections cause cancer?. Clinical Microbiology and Infection, 2015, 21, 967-968.	6.0	1
119	Dynamics of HIV DNA and Residual Viremia in Patients Treated With a Raltegravir-Containing Regimen. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, e18-e20.	2.1	4
120	Variation in interferon sensitivity and induction between Usutu and West Nile (lineages 1 and 2) viruses. Virology, 2015, 485, 189-198.	2.4	24
121	TLR9 is expressed in human papillomavirus-positive cervical cells and is overexpressed in persistent infections. Immunobiology, 2015, 220, 363-368.	1.9	45
122	Is hepatitis C virus eradication around the corner only 25 years after its discovery?. International Journal of Antimicrobial Agents, 2015, 45, 111-112.	2.5	19
123	Mechanisms of Action of Antiviral Agents. , 2015, , 197-210.		Ο
124	In VitroAssessment of the Biologic Activity of Interferon Beta Formulations used for the Treatment of Relapsing Multiple Sclerosis. Journal of Immunoassay and Immunochemistry, 2014, 35, 288-299.	1.1	7
125	Recurrent wheezing 36Âmonths after bronchiolitis is associated with rhinovirus infections and blood eosinophilia. Acta Paediatrica, International Journal of Paediatrics, 2014, 103, 1094-1099.	1.5	52
126	Host genetics: deciphering the variability in susceptibility to infections. Clinical Microbiology and Infection, 2014, 20, 1235-1236.	6.0	5

#	Article	IF	CITATIONS
127	Hepatitis C virus present in the sera of infected patients interferes with the autophagic process of monocytes impairing their in-vitro differentiation into dendritic cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 1348-1355.	4.1	21
128	Interferon lambda 1 expression in cervical cells differs between low-risk and high-risk human papillomavirus-positive women. Medical Microbiology and Immunology, 2014, 203, 177-184.	4.8	27
129	Early collection of saliva specimens from Bell's palsy patients: Quantitative analysis of HHV-6, HSV-1, and VZV. Journal of Medical Virology, 2014, 86, 1752-1758.	5.0	25
130	Interferon lambda 1–3 expression in infants hospitalized for RSV or HRV associated bronchiolitis. Journal of Infection, 2014, 68, 467-477.	3.3	61
131	Human OX40 tunes the function of regulatory T cells in tumor and nontumor areas of hepatitis C virus-infected liver tissue. Hepatology, 2014, 60, 1494-1507.	7.3	70
132	From â€~purging' to â€~endogenization' of the HIV genome: a new approach to HIV eradication?. Clinical Microbiology and Infection, 2014, 20, 1278-1279.	6.0	1
133	V3 Net Charge: Additional Tool in HIV-1 Tropism Prediction. AIDS Research and Human Retroviruses, 2014, 30, 1203-1212.	1.1	8
134	Cytomegalovirus in Bone Marrow Cells Correlates with Cytomegalovirus in Peripheral Blood Leukocytes. Journal of Clinical Microbiology, 2014, 52, 2183-2185.	3.9	4
135	Molecular epidemiology and genetic diversity of human rhinovirus affecting hospitalized children in Rome. Medical Microbiology and Immunology, 2013, 202, 303-311.	4.8	20
136	Antiviral activity of the interferon $\hat{l}\pm$ family: biological and pharmacological aspects of the treatment of chronic hepatitis C. Expert Opinion on Biological Therapy, 2013, 13, 693-711.	3.1	21
137	Emerging new technologies in clinical virology. Clinical Microbiology and Infection, 2013, 19, 8-9.	6.0	6
138	Usutu virus growth in human cell lines: induction of and sensitivity to type I and III interferons. Journal of General Virology, 2013, 94, 789-795.	2.9	16
139	Viruses and Immunity in Transplant Patients. Clinical and Developmental Immunology, 2013, 2013, 1-2.	3.3	0
140	Short Communication: Analysis of the Integrase Gene from HIV Type 1-Positive Patients Living in a Rural Area of West Cameroon. AIDS Research and Human Retroviruses, 2012, 28, 1729-1733.	1.1	11
141	Antiviral therapy: old and current issues. International Journal of Antimicrobial Agents, 2012, 40, 95-102.	2.5	62
142	Evaluation of interleukin 28B single nucleotide polymorphisms in infants suffering from bronchiolitis. Virus Research, 2012, 165, 236-240.	2.2	13
143	High detection rate of human papillomavirus in anal brushings from women attending a proctology clinic. Journal of Infection, 2012, 65, 255-261.	3.3	5
144	Human Gyrovirus DNA in Human Blood, Italy. Emerging Infectious Diseases, 2012, 18, 956-959.	4.3	42

#	Article	IF	CITATIONS
145	Evaluation of viral load in infants hospitalized with bronchiolitis caused by respiratory syncytial virus. Medical Microbiology and Immunology, 2012, 201, 311-317.	4.8	51
146	Diagnosis of anal human papillomavirus infection: polymerase chain reaction or cytology?. International Journal of Infectious Diseases, 2011, 15, e232-e235.	3.3	3
147	Incidence and predisposing factors for severe disease in previously healthy term infants experiencing their first episode of bronchiolitis. Acta Paediatrica, International Journal of Paediatrics, 2011, 100, e17-23.	1.5	49
148	Rhinovirus frequently detected in elderly adults attending an emergency department. Journal of Medical Virology, 2011, 83, 2043-2047.	5.0	19
149	<i>In Vitro</i> Sensitivity of Human Metapneumovirus to Type I Interferons. Viral Immunology, 2011, 24, 159-164.	1.3	21
150	Pandemic 2009 H1N1 Influenza Virus Is Resistant to the Antiviral Activity of Several Interferon Alpha Subtypes. Journal of Interferon and Cytokine Research, 2011, 31, 475-479.	1.2	8
151	Expression of the mRNA Levels for MDR1, MRP1, MRP4, and MRP5 IN HIV Antiretroviral Naive Patients: Follow-up at 48 Weeks After the Beginning of Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, e54-e56.	2.1	3
152	Mutational Resistance Pattern of HIV Type 1 in CD14 ⁺ Monocytes, CD4 ⁺ T Cells, and Plasma from Treated Patients. AIDS Research and Human Retroviruses, 2010, 26, 625-634.	1.1	6
153	Differential expression of interferon-induced microRNAs in patients with chronic hepatitis C virus infection treated with pegylated interferon alpha. Virology Journal, 2010, 7, 311.	3.4	57
154	Torquetenovirus viremia kinetics after autologous stem cell transplantation are predictable and may serve as a surrogate marker of functional immune reconstitution. Journal of Clinical Virology, 2010, 47, 189-192.	3.1	92
155	Gene Expression of Nucleic Acid-Sensing Pattern Recognition Receptors in Children Hospitalized for Respiratory Syncytial Virus-Associated Acute Bronchiolitis. Vaccine Journal, 2009, 16, 816-823.	3.1	52
156	Expression Levels of TLRs Involved in Viral Recognition in PBMCs from HIV-1-Infected Patients Failing Antiretroviral Therapy. Intervirology, 2009, 52, 107-114.	2.8	22
157	Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study. BMC Neurology, 2009, 9, 54.	1.8	25
158	Human Papillomaviruses and genital co-infections in gynaecological outpatients. BMC Infectious Diseases, 2009, 9, 16.	2.9	92
159	Unsung Hero Robert C. Gallo. Science, 2009, 323, 206-207.	12.6	2
160	Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy. Journal of Medical Virology, 2008, 80, 766-771.	5.0	38
161	Human bocavirus infection in hospitalized children in Italy. Influenza and Other Respiratory Viruses, 2008, 2, 175-179.	3.4	28
162	Neutralizing and Binding Antibodies to Interferon Beta in Patients with Multiple Sclerosis: A Comparison of Assay Results from Three Italian Centres. Journal of Immunoassay and Immunochemistry, 2008, 30, 40-50.	1.1	6

#	Article	IF	CITATIONS
163	Study of the Genotypic Resistant Pattern in HIV-Infected Women and Children from Rural West Cameroon. AIDS Research and Human Retroviruses, 2008, 24, 781-785.	1.1	13
164	Severe Acute Respiratory Syndrome Coronavirus Elicits a Weak Interferon Response Compared to Traditional Interferon-Inducing Viruses. Intervirology, 2008, 51, 217-223.	2.8	8
165	Modifications of HIV-1 DNA and Provirus-Infected Cells During 24 Months of Intermittent Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 48, 68-71.	2.1	4
166	Type-specific human papillomavirus-DNA load in anal infection in HIV-positive men. Aids, 2008, 22, 1929-1935.	2.2	30
167	Biological basis for a proper clinical application of alpha interferons. New Microbiologica, 2008, 31, 305-18.	0.1	15
168	Genotypic Resistance of Archived and Circulating Viral Strains in the Blood of Treated HIV-Infected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 518-524.	2.1	35
169	A BRIEF COMMUNICATION. Experimental Biology and Medicine, 2007, 232, 1355-1359.	2.4	15
170	The Synergistic Interaction of Interferon Types I and II Leads to Marked Reduction in Severe Acute Respiratory Syndrome-Associated Coronavirus Replication and Increase in the Expression of mRNAs for Interferon-Induced Proteins. Intervirology, 2007, 50, 156-160.	2.8	14
171	Detection and typing by molecular techniques of respiratory viruses in children hospitalized for acute respiratory infection in Rome, Italy. Journal of Medical Virology, 2007, 79, 463-468.	5.0	127
172	Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies. Journal of Neurology, 2007, 254, 597-604.	3.6	25
173	Immunogenicity comparison of interferon beta-1a preparations using the BALB/c mouse model: assessment of a new formulation for use in multiple sclerosis. New Microbiologica, 2007, 30, 241-6.	0.1	13
174	Neutralizing antibodies to interferon alpha in a chronic hepatitis C patient non-responder to pegylated interferon. Journal of Hepatology, 2006, 45, 759-761.	3.7	12
175	Direct sequencing of HPV DNA detected in gynaecologic outpatients in Rome, Italy. Microbes and Infection, 2006, 8, 2517-2521.	1.9	27
176	Predictors of long–term clinical response to interferon beta therapy in relapsing multiple sclerosis. Journal of Neurology, 2006, 253, 287-293.	3.6	113
177	Neutralising antibodies to IFN-β in patients with multiple sclerosis. Expert Opinion on Biological Therapy, 2006, 6, 773-785.	3.1	3
178	Considerations on the development of serum antibodies to interferon-beta. New Microbiologica, 2005, 28, 183-92.	0.1	7
179	MxA and PKR Expression in Chronic Hepatitis C. Journal of Interferon and Cytokine Research, 2004, 24, 659-663.	1.2	18
180	Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antiviral Therapy, 2004, 9, 1003-11.	1.0	48

#	Article	IF	CITATIONS
181	Increased Sensitivity of Sars-Coronavirus to a Combination of Human Type I and Type II Interferons. Antiviral Therapy, 2004, 9, 1003-1011.	1.0	77
182	Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. Journal of the Neurological Sciences, 2003, 215, 3-8.	0.6	61
183	Serum Interferon (IFN)-Neutralizing Antibodies and Bioactivities of IFNs in Patients with Severe Type II Essential Mixed Cryoglobulinemia. Vaccine Journal, 2003, 10, 70-77.	3.1	7
184	P-Glycoprotein Expression by Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus-Infected Patients Is Independent from Response to Highly Active Antiretroviral Therapy. Vaccine Journal, 2003, 10, 191-192.	3.1	5
185	Selection of a T-Cell Line Resistant to Stavudine and Zidovudine by Prolonged Treatment with Stavudine. Antiviral Therapy, 2002, 7, 105-111.	1.0	2
186	Dynamics of Persistent TT Virus Infection, as Determined in Patients Treated with Alpha Interferon for Concomitant Hepatitis C Virus Infection. Journal of Virology, 2001, 75, 11999-12004.	3.4	84
187	Decay of HIV Type 1 DNA and Development of Drug-Resistant Mutants in Patients with Primary HIV Type 1 Infection Receiving Highly Active Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2001, 17, 1599-1604.	1.1	17
188	May the Drug Transporter P Glycoprotein Affect the Antiviral Activity of Human Immunodeficiency Virus Type 1 Proteinase Inhibitors?. Antimicrobial Agents and Chemotherapy, 2000, 44, 473-474.	3.2	17
189	Approval Standards for Alfa Interferon Subtypes. Drug Information Journal, 2000, 34, 1231-1246.	0.5	1
190	Influence of Hepatitis C Virus (HCV) Genotype, HCV RNA Load, and Alanine Aminotransferase Level on Reduction of HCV RNA after a Single Administration of Interferonâ€î±. Journal of Infectious Diseases, 1999, 180, 1411-1412.	4.0	4
191	Correlation of Interferon-Induced Expression of MxA mRNA in Peripheral Blood Mononuclear Cells with the Response of Patients with Chronic Active Hepatitis C to IFN-alpha Therapy. Journal of Interferon and Cytokine Research, 1999, 19, 243-251.	1.2	66
192	Development of neutralizing and binding antibodies to interferon (IFN) in patients undergoing IFN therapy. Antiviral Research, 1994, 24, 235-244.	4.1	30
193	2′,5′-Oligoadenylate Synthetase Activity as a Responsive Marker During Interferon Therapy for Chronic Hepatitis C. Journal of Interferon Research, 1993, 13, 57-60.	1.2	27
194	The HIV-1 Provirus Excised by a Single CRISPR/Cas9 RNA Guide Persists in the Host Cell and May Be Reactivated. SSRN Electronic Journal, 0, , .	0.4	0
195	Comparison by Age of the Local Interferon Response to SARS-CoV-2 Suggests a Role for IFN-ε and -ω. Frontiers in Immunology, 0, 13, .	4.8	14